Cancer care has increasingly moved toward personalized approaches that consider the biological characteristics of an individual's disease. Theranostics is one such approach, combining therapy and diagnostics to help identify cancer cells and potentially treat them using the same biological target. Instead of relying only on conventional imaging or treatments, theranostics uses specific molecular markers to guide clinical decisions. This approach is particularly relevant in cancers where well-defined molecular targets can be identified through specialized imaging.
Theranostics generally involves two connected stages. First, a diagnostic compound is used with medical imaging to determine whether a particular target is present in cancer cells. If the target is identified, a therapeutic compound designed to interact with the same target may be considered.
This approach can help healthcare professionals determine whether a patient is likely to benefit from a targeted therapy. It also illustrates how imaging can become part of treatment planning rather than being used only to locate tumors.
Key roles of theranostics include:
One well-known example involves targeting certain receptors found on cancer cells using radiolabeled compounds. A diagnostic version can help visualize the target, while a therapeutic version can deliver radiation to cells carrying that target. The exact application depends on the cancer type, available treatment, patient characteristics, and clinical guidance.
Theranostics represents an important area of research because it connects diagnosis, imaging, and treatment within a single targeted framework. By identifying molecular characteristics before treatment, clinicians may gain additional information when considering whether a therapy could be suitable.
However, theranostics is not appropriate for every cancer or every patient. Its use depends on whether a suitable biological target can be detected and whether an approved or clinically appropriate therapy exists for that target.
Important considerations include:
As research progresses, theranostics may contribute to increasingly individualized cancer care. Advances in molecular imaging, radiopharmaceutical development, and cancer biology could expand the number of cancers that can be evaluated using this approach. Continued clinical research is important for determining which patients are most likely to benefit and how treatments can be delivered safely.
Overall, theranostics demonstrates how modern cancer care is increasingly connecting diagnosis with treatment decisions. By using biological targets to guide both imaging and therapy, it offers a framework for more individualized approaches to cancer management. Its role will continue to develop as researchers evaluate new targets, treatments, and clinical applications.